Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505502 | 0.86 | FGFR1 (0.38) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL838368 | 0.78 | FGFR1 (0.49) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL837898 | 0.74 | CDK8 (0.55) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL12448288 | 0.70 | FGFR1 (0.66) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL13702375 | 0.69 | HDAC8 (0.68) | PIK3CGCDK8NR4A2FYNPIK3CA | |
| SCHEMBL837839 | 0.69 | FGFR1 (0.65) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL28655081 | 0.66 | FGFR1 (0.53) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL3757138 | 0.66 | FGFR1 (0.50) | FGFR1FGFR3PIK3CGCDK8NTRK1 | |
| SCHEMBL9949560 | 0.65 | CDK8 (0.55) | FGFR1CDK8NTRK1JAK2GRM5 | |
| SCHEMBL837206 | 0.65 | FGFR3 (0.70) | FGFR1FGFR3CDK8NTRK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | FGFR1 20/4885FGFR3 81/4885PIK3CG 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.